Kiniksa Pharmaceuticals International, plc
76.73USD
-4.0600 (-5.03%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on KNSA.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 220.2M | 270.3M | 423.2M | 677.6M | 996.2M | 1.2B |
| Q1 | 32.2M | 48.3M | 79.9M | 137.8M | 214.3M | — |
| Q2 | 27.0M | 71.5M | 108.6M | 156.8M | — | — |
| Q3 | 99.1M | 67.0M | 112.2M | 180.9M | 260.6M | — |
| Q4 | 61.9M* | 83.4M* | 122.5M* | 202.1M* | 277.6M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 2.60 | .200 | -.600 | .750 | 1.17 | 1.63 |
| Q1 | -.360 | -.180 | -.250 | .110 | .270 | — |
| Q2 | -.290 | .210 | -.060 | .230 | — | — |
| Q3 | 3.18 | -.200 | -.180 | .230 | .313 | — |
| Q4 | .063* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| .351* |
| -.124* |
| .180* |
| .295 |
| — |
Debt level and coverage